(Total Views: 252)
Posted On: 07/30/2021 6:04:11 PM
Post# of 1354
NetworkNewsBreaks – Pressure BioSciences Inc.’s (PBIO) Business Model Expected to Generate up to $3M in Incremental Revenue
Pressure BioSciences (OTCQB: PBIO) (“PBI”), a developer of innovative, pressure-based solutions for the worldwide life science and other industries, recently announced the development of the ultra-potent antioxidant astaxanthin (“AsX”) as an extremely fine and uniform nanoemulsion. The nanoemulsions produced by its trademarked Ultra Shear Technology(TM) (“UST”) platform encapsulate AsX in extremely small oil droplets ranging in size from 30-60 nm in diameter. “The enhanced oral bioavailability of AsX corresponding to droplet size reduction is well-established and has been published. Pressure BioSciences anticipates the use of its technology will make it possible for nutraceutical companies to exercise greater control over their dosing and find ways to lower their costs, which may in turn lower the costs for consumers,” reads a recent article. “The company has received pre-orders for 12 BaroShear K45 systems, the company’s first commercial application of its UST-based processing system, and expects to be able to fulfill the orders beginning late this year through a lease/royalty business model, which it expects to generate up to $3 million in incremental revenue in late 2021 and early 2022.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences (OTCQB: PBIO) (“PBI”), a developer of innovative, pressure-based solutions for the worldwide life science and other industries, recently announced the development of the ultra-potent antioxidant astaxanthin (“AsX”) as an extremely fine and uniform nanoemulsion. The nanoemulsions produced by its trademarked Ultra Shear Technology(TM) (“UST”) platform encapsulate AsX in extremely small oil droplets ranging in size from 30-60 nm in diameter. “The enhanced oral bioavailability of AsX corresponding to droplet size reduction is well-established and has been published. Pressure BioSciences anticipates the use of its technology will make it possible for nutraceutical companies to exercise greater control over their dosing and find ways to lower their costs, which may in turn lower the costs for consumers,” reads a recent article. “The company has received pre-orders for 12 BaroShear K45 systems, the company’s first commercial application of its UST-based processing system, and expects to be able to fulfill the orders beginning late this year through a lease/royalty business model, which it expects to generate up to $3 million in incremental revenue in late 2021 and early 2022.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
